COCHLEAR LIMITED (COH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.41
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$272.29

01 Dec
2023

-0.750

OPEN

$273.81

-0.27%

HIGH

$274.70

179,545

LOW

$270.39

TARGET
$236.90 -13.0% downside
Franking for last dividend paid out: 70%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
COH: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 457.1 553.5 xxx
DPS (cps) xxx 330.0 388.4 xxx
EPS Growth xxx 4.0% 21.1% xxx
DPS Growth xxx 10.0% 17.7% xxx
PE Ratio xxx N/A 49.2 xxx
Dividend Yield xxx N/A 1.4% xxx
Div Pay Ratio(%) xxx 72.2% 70.2% xxx

Dividend yield today if purchased 3 years ago: 1.51%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.21

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 18/09 - ex-div 175c (franking 70%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx457.1
DPS All xxxxxxxxxxxxxxx330.0
Sales/Revenue xxxxxxxxxxxxxxx1,955.7 M
Book Value Per Share xxxxxxxxxxxxxxx2,662.9
Net Operating Cash Flow xxxxxxxxxxxxxxx362.4 M
Net Profit Margin xxxxxxxxxxxxxxx15.37 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx17.50 %
Return on Invested Capital xxxxxxxxxxxxxxx15.94 %
Return on Assets xxxxxxxxxxxxxxx11.94 %
Return on Equity xxxxxxxxxxxxxxx17.50 %
Return on Total Capital xxxxxxxxxxxxxxx21.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx115.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx39 M
Long Term Debt xxxxxxxxxxxxxxx163 M
Total Debt xxxxxxxxxxxxxxx202 M
Goodwill - Gross xxxxxxxxxxxxxxx256 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx556 M
Price To Book Value xxxxxxxxxxxxxxx8.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx95.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx488 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,055 M
Research & Development xxxxxxxxxxxxxxx245 M
Investments - Total xxxxxxxxxxxxxxx99 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

16/08/2023

1

Add

$269.40

-1.06%

Following strong sales growth across all geographies and business segments, explains Morgans, FY23 results for Cochlear landed at the top end of guidance.

The broker anticipates a solid earnings trajectory for the company as fundamentals continue to improve and covid becomes but a memory.

Ongoing solid revenue growth and improving profitability are expected, as Cochlear Implant (CI) trading conditions and demand for upgrades remains strong.

Over FY23, Cochlear Implants benefited from improved clinical capacity, market growth/share and covid catch-up surgeries. At the same time, Services leveraged the Nucleus 8 launch and a strong product offering in Acoustics.

The target rises to $269.40 from $250.60. Add.

FORECAST
Morgans forecasts a full year FY24 dividend of 388.00 cents and EPS of 553.80 cents.
Morgans forecasts a full year FY25 dividend of 434.00 cents and EPS of 617.80 cents.

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

COH STOCK CHART

FNArena News on COH

1
Rudi’s View: Quality In Stocks; What Is It Good For?

Nov 22 2023 - Rudi's View
2
ESG Focus: Rounding Up A Psychosocial FY23 Season

Nov 20 2023 - ESG Focus
3
ESG Focus: Day Of The TRIFRS

Nov 09 2023 - ESG Focus
4
Australian Broker Call *Extra* Edition – Nov 08, 2023

Nov 08 2023 - Daily Market Reports
5
Rudi’s View: Outlook 2024, Is History Our Guide?

Nov 08 2023 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest